Shots:

• Tiziana has completed its clinical study in Brazil assessing nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients
• The study enrolled 39 patients with mod. to sev. COVID-19 who did not require the use of a ventilator at the beginning of the study with anticipated results available in Jan’2021
• The 1EPs of the study was safety of the treatment while the 2EPs were to evaluate the effect on disease severity symptoms- nasal tolerance- sense of smell- and biomarkers for disease progression. Anecdotal feedback from Foralumab-treated patients was positive suggesting that the treatment was well-tolerated

 ­ Ref: Tiziana | Image: Share Talk